doi: 10.1038/S41598-019-55524-W 116 O'NeilPMBirkenfeldALMcGowanBMosenzonOPedersenSDWhartonSet al
There is also a bigger ongoing study with over 2,000 people to confirm these results and gather more information, which will continue for about 89 weeks
[DOI] [PubMed] [Google Scholar] 3.Hornby C, Botfield H, O'Reilly MW, et al
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications originally developed for type 2 diabetes management
In particular, they found that the activation of GLP-1R promoted the secretion of atrial natriuretic peptide (ANP) and lowered blood pressure
At minimum: IGF-1 every 4 weeks, fasting glucose and insulin every 2 weeks initially (monthly once stable), HbA1c every 6 weeks, liver enzymes monthly, and comprehensive metabolic panel quarterly